Global Cancer Generics Market Outlook 2018
With the advent of novel and innovative technologies, industries like healthcare and pharmaceutical are scaling newer heights. One such market is the oncology market. With global cancer incidences rising to almost 14.1 Million in 2012 and several blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience skyrocketing growth.
According to our latest research report “Global Cancer Generics Market Outlook 2018”, the global oncology market touched a mark of US$ 91 Billion in 2013 and is poised to grow at a CAGR of approximately 6% over the next 5 year period. On the other hand, the market for cancer generics is expected to grow at 12%, reaching US$ 21 Billion by 2018. Patent expiry, low cost, and better life expectancy would be the major boosting factors for the cancer generics industry.
Our report essentially elicits the cancer industry under 2 heads viz. global oncology market and global caner generics market. Hereunder, cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to major indications is also discussed in depth, with emphasis on current and future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.
Apart from the above mentioned study parameters the dossier also contains an analysis of the top notch global cancer generics manufacturers. On a holistic basis, the report is primarily inclined towards an in-depth study of the global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.
According to our latest research report “Global Cancer Generics Market Outlook 2018”, the global oncology market touched a mark of US$ 91 Billion in 2013 and is poised to grow at a CAGR of approximately 6% over the next 5 year period. On the other hand, the market for cancer generics is expected to grow at 12%, reaching US$ 21 Billion by 2018. Patent expiry, low cost, and better life expectancy would be the major boosting factors for the cancer generics industry.
Our report essentially elicits the cancer industry under 2 heads viz. global oncology market and global caner generics market. Hereunder, cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to major indications is also discussed in depth, with emphasis on current and future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.
Apart from the above mentioned study parameters the dossier also contains an analysis of the top notch global cancer generics manufacturers. On a holistic basis, the report is primarily inclined towards an in-depth study of the global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GLOBAL CANCER DRUGS MARKET OUTLOOK 2018
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. GLOBAL CANCER GENERICS MARKET ANALYSIS 2018
5. CANCER GENERIC DRUGS INDUSTRY
5.1 Oral Generic Drugs
5.1.1 Arimidex (Anastrozole)
5.1.2 Femara (Letrozole)
5.1.3 Hycamtin (Topotecan)
5.1.4 Stivarga (Regorafenib)
5.1.5 Tarceva (Erlotinib)
5.1.6 Xalkori (Crizotinib)
5.1.7 Xeloda (Capecitabine)
5.2 Generic Injectables
5.2.1 Camptosar (Irinotecan Hydrochloride)
5.2.2 Eloxatin (Oxaliplatin)
5.2.3 Gemzar (Gemcitabine Hydrochloride)
5.2.4 Navelbine (Vinorelbine Tartrate)
5.2.5 Platinol (Cisplatin)
5.2.6 Taxol (Paclitaxel)
5.2.7 Taxotere (Docetaxel)
6. CANCER GENERICS MARKET: MAJOR INDICATIONS
6.1 Lung Cancer
6.1.1 Incidence Outlook
6.1.2 Commercialized Drugs
6.2 Breast Cancer
6.2.1 Incidence Outlook
6.2.2 Commercialized Drugs
6.3 Colorectal Cancer
6.3.1 Incidence Outlook
6.3.2 Commercialized Drugs
6.4 Stomach Cancer
6.4.1 Incidence Outlook
6.4.2 Commercialized Drugs
6.5 Prostate Cancer
6.5.1 Incidence Outlook
6.5.2 Commercialized Drugs
7. MARKET DYNAMICS
7.1 Indian Generic Cancer Drug Introduced in the US Market
7.2 Launch of Generic Drugs for Oncology
7.3 Increasing Cancer Burden Paving Way for Generics
7.4 Patent Expiry of Blockbuster Oncology Drugs
7.5 Strategic Collaborations
8. KEY PLAYERS
8.1 Fresenius Kabi AG
8.1.1 Business Overview
8.1.2 Key Financials
8.1.3 Strategic Developments
8.2 Actavis Plc.
8.2.1 Business Overview
8.2.2 Key Financials
8.2.3 Strategic Developments
8.3 Hospira
8.3.1 Business Overview
8.3.2 Key Financials
8.3.3 Strategic Developments
8.4 Teva Pharmaceutical Industries Ltd.
8.4.1 Business Overview
8.4.2 Key Financials
8.4.3 Strategic Developments
8.5 Mylan
8.5.1 Business Overview
8.5.2 Key Financials
8.5.3 Strategic Developments
8.6 Sun Pharmaceuticals
8.6.1 Business Overview
8.6.2 Key Financials
8.6.3 Strategic Developments
2. RESEARCH METHODOLOGY
3. GLOBAL CANCER DRUGS MARKET OUTLOOK 2018
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. GLOBAL CANCER GENERICS MARKET ANALYSIS 2018
5. CANCER GENERIC DRUGS INDUSTRY
5.1 Oral Generic Drugs
5.1.1 Arimidex (Anastrozole)
5.1.2 Femara (Letrozole)
5.1.3 Hycamtin (Topotecan)
5.1.4 Stivarga (Regorafenib)
5.1.5 Tarceva (Erlotinib)
5.1.6 Xalkori (Crizotinib)
5.1.7 Xeloda (Capecitabine)
5.2 Generic Injectables
5.2.1 Camptosar (Irinotecan Hydrochloride)
5.2.2 Eloxatin (Oxaliplatin)
5.2.3 Gemzar (Gemcitabine Hydrochloride)
5.2.4 Navelbine (Vinorelbine Tartrate)
5.2.5 Platinol (Cisplatin)
5.2.6 Taxol (Paclitaxel)
5.2.7 Taxotere (Docetaxel)
6. CANCER GENERICS MARKET: MAJOR INDICATIONS
6.1 Lung Cancer
6.1.1 Incidence Outlook
6.1.2 Commercialized Drugs
6.2 Breast Cancer
6.2.1 Incidence Outlook
6.2.2 Commercialized Drugs
6.3 Colorectal Cancer
6.3.1 Incidence Outlook
6.3.2 Commercialized Drugs
6.4 Stomach Cancer
6.4.1 Incidence Outlook
6.4.2 Commercialized Drugs
6.5 Prostate Cancer
6.5.1 Incidence Outlook
6.5.2 Commercialized Drugs
7. MARKET DYNAMICS
7.1 Indian Generic Cancer Drug Introduced in the US Market
7.2 Launch of Generic Drugs for Oncology
7.3 Increasing Cancer Burden Paving Way for Generics
7.4 Patent Expiry of Blockbuster Oncology Drugs
7.5 Strategic Collaborations
8. KEY PLAYERS
8.1 Fresenius Kabi AG
8.1.1 Business Overview
8.1.2 Key Financials
8.1.3 Strategic Developments
8.2 Actavis Plc.
8.2.1 Business Overview
8.2.2 Key Financials
8.2.3 Strategic Developments
8.3 Hospira
8.3.1 Business Overview
8.3.2 Key Financials
8.3.3 Strategic Developments
8.4 Teva Pharmaceutical Industries Ltd.
8.4.1 Business Overview
8.4.2 Key Financials
8.4.3 Strategic Developments
8.5 Mylan
8.5.1 Business Overview
8.5.2 Key Financials
8.5.3 Strategic Developments
8.6 Sun Pharmaceuticals
8.6.1 Business Overview
8.6.2 Key Financials
8.6.3 Strategic Developments
LIST OF FIGURES:
Figure 3-1: Global - Number of New Cancer Cases (Million), 2012 & 2025
Figure 3-2: Global - Cancer Incidences by Gender (Million), 2012
Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2008-2013
Figure 3-4: Global - Cancer Drugs Market (Billion US$), 2014-2018
Figure 3-5: Cancer Drugs Market Share by Geography (%), 2013
Figure 3-6: Cancer Drugs Market Share by Geography (%), 2018
Figure 3-7: Global - Cancer Treatment Modalities Revenue Share (%), 2013
Figure 4-1: Global - Cancer Generics Market (Billion US$), 2013-2018
Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2012 & 2020
Figure 6-2: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-3: Global - Number of New Breast Cancer Cases (Million), 2012 & 2020
Figure 6-4: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-5: Global - Number of New Colorectal Cancer Cases (Million), 2012 & 2020
Figure 6-6: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-7: Global - Number of New Stomach Cancer Cases (Million), 2012 & 2020
Figure 6-8: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-9: Global - Number of New Prostate Cancer Cases (Million), 2012 & 2020
Figure 6-10: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
Figure 8-1: Fresenius Kabi - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-2: Fresenius Kabi - Revenue Share by Region (%), 2013
Figure 8-3: Fresenius Kabi - Revenue Share by Business Segment (%), 2013
Figure 8-4: Actavis - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-5: Actavis - Revenue Share by Region (%), 2013
Figure 8-6: Actavis - Revenue Share by Business Segment (%), 2013
Figure 8-7: Hospira - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-8: Hospira - Revenue Share by Region (%), 2013
Figure 8-9: Hospira - Revenue Share by Business Segment (%), 2013
Figure 8-10: Teva - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-11: Teva - Revenue Share by Region (%), 2013
Figure 8-12: Hospira - Revenue Share by Business Segment (%), 2013
Figure 8-13: Mylan - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-14: Mylan - Revenue Share by Region (%), 2013
Figure 8-15: Mylan - Revenue Share by Business Segment (%), 2013
Figure 8-16: Sun Pharma - Sales & Net Income (Billion US$), 2012-13/ 2013-14
Figure 8-17: Sun Pharma - Revenue Share by Business Segment (%), 2013-14
Figure 3-1: Global - Number of New Cancer Cases (Million), 2012 & 2025
Figure 3-2: Global - Cancer Incidences by Gender (Million), 2012
Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2008-2013
Figure 3-4: Global - Cancer Drugs Market (Billion US$), 2014-2018
Figure 3-5: Cancer Drugs Market Share by Geography (%), 2013
Figure 3-6: Cancer Drugs Market Share by Geography (%), 2018
Figure 3-7: Global - Cancer Treatment Modalities Revenue Share (%), 2013
Figure 4-1: Global - Cancer Generics Market (Billion US$), 2013-2018
Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2012 & 2020
Figure 6-2: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-3: Global - Number of New Breast Cancer Cases (Million), 2012 & 2020
Figure 6-4: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-5: Global - Number of New Colorectal Cancer Cases (Million), 2012 & 2020
Figure 6-6: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-7: Global - Number of New Stomach Cancer Cases (Million), 2012 & 2020
Figure 6-8: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-9: Global - Number of New Prostate Cancer Cases (Million), 2012 & 2020
Figure 6-10: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
Figure 8-1: Fresenius Kabi - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-2: Fresenius Kabi - Revenue Share by Region (%), 2013
Figure 8-3: Fresenius Kabi - Revenue Share by Business Segment (%), 2013
Figure 8-4: Actavis - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-5: Actavis - Revenue Share by Region (%), 2013
Figure 8-6: Actavis - Revenue Share by Business Segment (%), 2013
Figure 8-7: Hospira - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-8: Hospira - Revenue Share by Region (%), 2013
Figure 8-9: Hospira - Revenue Share by Business Segment (%), 2013
Figure 8-10: Teva - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-11: Teva - Revenue Share by Region (%), 2013
Figure 8-12: Hospira - Revenue Share by Business Segment (%), 2013
Figure 8-13: Mylan - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-14: Mylan - Revenue Share by Region (%), 2013
Figure 8-15: Mylan - Revenue Share by Business Segment (%), 2013
Figure 8-16: Sun Pharma - Sales & Net Income (Billion US$), 2012-13/ 2013-14
Figure 8-17: Sun Pharma - Revenue Share by Business Segment (%), 2013-14
LIST OF TABLES:
Table 3-1: Most Prevalent Types of Cancer
Table 3-2: Top 10 Countries with Highest Cancer Prevalence Rates
Table 5-1: List of Companies Dealing in Generic Arimidex
Table 5-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 5-3: List of Companies Dealing in Generic Femara
Table 5-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 5-5: List of Companies Dealing in Generic Hycamtin
Table 5-6: List of Companies Dealing in Generic Xeloda
Table 5-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 5-8: List of Companies Dealing in Generic Camptosar
Table 5-9: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 5-10: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 5-11: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 5-12: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 5-13: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 5-14: List of Companies Dealing in Generic Platinol (Cisplatin)
Table 5-15: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 5-16: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 5-17: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 5-18: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-1: Top 10 Countries by Lung Cancer Incidences (2012)
Table 6-2: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 6-3: Top 10 Countries by Breast Cancer Incidences (2012)
Table 6-4: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 6-5: Top 10 Countries by Colorectal Cancer Incidences (2012)
Table 6-6: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-7: Top 10 Countries by Stomach Cancer Incidences (2012)
Table 6-8: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-9: Top 10 Countries by Prostate Cancer Incidences (2012)
Table 6-10: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: Global - Key Cancer Drugs and Patent Expiry Status
Table 8-1: Fresnius Kabi Pharmaceuticals - Key Cancer Generic Drugs
Table 8-2: Actavis - Key Cancer Generic Drugs
Table 8-3: Hospira - Key Cancer Generic Products
Table 8-4: Teva Pharmaceuticals - Key Cancer Generic Drugs
Table 8-5: Mylan - Key Cancer Generic Drugs
Table 8-6: Sun Pharmaceuticals - Key Cancer Generic Drugs
Table 3-1: Most Prevalent Types of Cancer
Table 3-2: Top 10 Countries with Highest Cancer Prevalence Rates
Table 5-1: List of Companies Dealing in Generic Arimidex
Table 5-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 5-3: List of Companies Dealing in Generic Femara
Table 5-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 5-5: List of Companies Dealing in Generic Hycamtin
Table 5-6: List of Companies Dealing in Generic Xeloda
Table 5-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 5-8: List of Companies Dealing in Generic Camptosar
Table 5-9: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 5-10: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 5-11: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 5-12: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 5-13: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 5-14: List of Companies Dealing in Generic Platinol (Cisplatin)
Table 5-15: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 5-16: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 5-17: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 5-18: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-1: Top 10 Countries by Lung Cancer Incidences (2012)
Table 6-2: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 6-3: Top 10 Countries by Breast Cancer Incidences (2012)
Table 6-4: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 6-5: Top 10 Countries by Colorectal Cancer Incidences (2012)
Table 6-6: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-7: Top 10 Countries by Stomach Cancer Incidences (2012)
Table 6-8: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-9: Top 10 Countries by Prostate Cancer Incidences (2012)
Table 6-10: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: Global - Key Cancer Drugs and Patent Expiry Status
Table 8-1: Fresnius Kabi Pharmaceuticals - Key Cancer Generic Drugs
Table 8-2: Actavis - Key Cancer Generic Drugs
Table 8-3: Hospira - Key Cancer Generic Products
Table 8-4: Teva Pharmaceuticals - Key Cancer Generic Drugs
Table 8-5: Mylan - Key Cancer Generic Drugs
Table 8-6: Sun Pharmaceuticals - Key Cancer Generic Drugs
